MedTrace Logo

Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

NCT04438824 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-10-14

No results posted yet for this study

Summary

The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma.

"Funding Source - FDA OOPD"

Conditions

  • Well-differentiated/Dedifferentiated Liposarcoma

Interventions

DRUG

INCMGA00012

INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)

DRUG

Palbociclib

Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days

Sponsors & Collaborators

Principal Investigators

  • Sandra D'Angelo, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-17
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04438824 on ClinicalTrials.gov